Journal articles on the topic '634.049 3'
To see the other types of publications on this topic, follow the link: 634.049 3.
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic '634.049 3.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Deng, Lin, Bing Huang, Huai Yuan Zhao, Jia Yao Du, and Ling Gao. "Study on Modified PVA- H3BO3 Immobilization Microorganism Method for Hydrogen Production from Wastewater." Advanced Materials Research 634-638 (January 2013): 280–85. http://dx.doi.org/10.4028/www.scientific.net/amr.634-638.280.
Abstract:
A new immobilization microorganism (IM) method was built by adding sodium alginate, SiO2 and CaCO3 in gel and cross-linking with saturated H3BO3 aqueous solution with 2% CaCl2 for traditional PVA-H3BO3 method. The modified method was used for preparation IM for hydrogen production from waste water contained organics by sewage treatment plants’ sludge pretreated. The change rate of the IM balls diameter and unit hydrogen production were taken as the primary performance criterion of the IM. The modified IM method for hydrogen production from waste water contained organics was confirmed: 9% PVA and 0.9% sodium alginate for the embedding medium, saturated H3BO3 aqueous solution and 2% CaCl2 for cross-linking agent, and adding NaCO3 adjusting PH, 3%SiO2 and 0.5%CaCO3 for the support packing of IM balls, and the balls diameter of about 3mm. The modified IM balls had unit hydrogen production of 63.3% and total sugar removal rate of 143.4mL/h•L for washing model wastewater from ice cream factory, which contained 2000 mg/L total sugar and 5500mg/L COD, and higher mechanical strength. It were identified that the method could reduce outside surface’s shrink, and improve the homogeneous of inside endoporus structure of modified IM balls, and a similar inside microporosity and outside microporosity by SEM detection.
2
Bowmaker, Graham A., Effendy, John D. Kildea, Eban N. de Silva, and Allan H. White. "Lewis-Base Adducts of Group 11 Metal(I) Compounds. LXXI Synthesis, Spectroscopy and Structural Systematics of Some 1 : 2 Binuclear Adducts of Silver(I) Compounds with Triphenylarsine, [(Ph3As)2Ag(µ-X)2Ag(AsPh3)2], X = Cl, Br, I, SCN." Australian Journal of Chemistry 50, no. 6 (1997): 627. http://dx.doi.org/10.1071/c96037.
Abstract:
The syntheses and room-temperature single-crystal X-ray structural characterization of binuclear 1 : 2 adducts formed between silver(I) (pseudo-)halides, AgX, and triphenylarsine, AsPh3, for X = Cl, Br, I, SCN (1)–(4), are described. The chloride (1), obtained from 2-methylpyridine, is triclinic, P-1, a 10·410(2), b 12·716(2), c 14·196(6) Å, α 113·38(2), β 109·41(2), γ 75·08(1)°, Z = 1 (dimer); conventional R on F was 0·037 for No 3979 independent ‘observed’ (I > 3σ(I)) reflections. The bromide (2a), obtained from 2,6-dimethylpyridine, and iodide (3), obtained from a mixture of AgI/saturated KI in MeOH solutions, are isomorphous, monoclinic, P 21/c a≈ 24·2, b ≈ 13·9, c ≈ 20·2 Å, β ≈ 109·5°, Z = 4 dimers; R was 0·046 and 0·044 for No 5670 and 6039 respectively. The thiocyanate (4) has a similar cell, a 24·12(1), b 12·558(8), c 23·244(4) Å, β 110·11(3)°, Z = 4 dimers, R being 0·044 for No 7956; one of the thiocyanate ligands (which bridge in Ag-SCN-Ag mode) is disordered. A second polymorph of the bromide (2b) (from a mixture of AgBr/saturated KBr in H2O) is also monoclinic, P 21/c, a 14·121(8), b 25·577(3), c 21·968(2) Å, β 125·54(3)°, Z = 4 dimers (R was 0·047 for No 5715). Ag–As range between 2·568(1) and 2·633(1) Å throughout the series; in the isomorphous bromide and iodide, values increase slightly: 2·578(1)–2·611(1), cf. 2·601(2)-2·633(1) Å respectively. Ag–X are 2·568(2)-2·670(2) (Cl); 2·688(2)–2·715(2) (Br); 2·828(2)–2·856(1) Å (I); Ag-S, N for the ordered SCN group are 2·646(3), 2·255(6) Å. A redetermination of improved precision (R 0·035, No 6030) is reported for the triphenylphosphine/thiocyanate analogue. The far-infrared spectra of [(Ph3As)2Ag(µ-X)2Ag (AsPh3)2] show v(AgX) bands at 185, 145 (X = Cl), 145, 130, 106 (X = Br) and 121 cm-1 (X = I). The splittings and band widths reflect a decrease in the degree of distortion of the Ag(µ-X)2Ag units from a symmetrically bridged structure from X = Cl to I.
3
Long, Georgina V., F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo Antonio Ascierto, Luis Matamala, Pamela Salman, et al. "Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)." Journal of Clinical Oncology 40, no. 36_suppl (March 20, 2022): 360385. http://dx.doi.org/10.1200/jco.2022.40.36_suppl.360385.
Abstract:
360385 Background: RELATIVITY-047, a global, randomized, double-blind, phase II/III study, met its primary endpoint of progression-free survival (PFS). Relatlimab and nivolumab (RELA + NIVO) as a fixed-dose combination (FDC) demonstrated a significant PFS benefit (median PFS was 10.1 months [mo]; 95% CI, 6.4–15.7) with RELA + NIVO vs. 4.6 mo (95% CI, 3.4–5.6) with NIVO; hazard ratio (HR) 0.75 (95% CI, 0.6–0.9; p = .0055), with a manageable safety profile, compared to NIVO alone in patients with previously untreated metastatic or unresectable melanoma (Lipson EJ et al. J Clin Oncol 2021;39[15_suppl]:9503P). Here we report updated PFS and the first disclosure of secondary endpoints, overall survival (OS), and overall response rate (ORR). Methods: Patients were randomized 1:1 to receive RELA 160 mg + NIVO 480 mg FDC or NIVO 480 mg alone, given intravenously every 4 weeks, as previously described (Lipson EJ et al. J Clin Oncol 2021;39[15_suppl]:9503P). The primary endpoint of PFS per RECIST v1.1 was assessed by blinded independent central review (BICR). Secondary endpoints were OS and ORR by BICR, to be tested hierarchically. The OS boundary for statistical significance was p < .04302 (2-sided) based on 69% power for a target HR of 0.75. Results: Patients (714 patients) were randomly selected to receive RELA + NIVO (355 patients) or NIVO (359 patients). Median follow-up was 19.3 mo. Updated median PFS was 10.2 mo (95% CI, 6.5–14.8) with RELA + NIVO vs. 4.6 mo (95% CI, 3.5–6.4) with NIVO (HR 0.78; 95% CI, 0.6–0.9). Median OS was not reached (NR; 95% CI, 34.2–NR) with RELA + NIVO vs. 34.1 mo (95% CI. 25.2–NR) with NIVO (HR 0.80; 95% CI, 0.6–1.0; p = .0593). OS rates at 12 mo were 77.0% (95% CI, 72.2–81.1) vs. 71.6% (95% CI, 66.6–76.0) and at 24 mo were 63.7% (95% CI, 58.1–68.7) vs. 58.3% (95% CI, 52.7–63.4) with RELA + NIVO vs. NIVO, respectively. Subsequent systemic therapy rates and types were generally similar between treatment groups. Confirmed ORR per BICR was 43.1% (95% CI, 37.9–48.4) with RELA + NIVO vs. 32.6% (95% CI, 27.8–37.7) with NIVO. Complete responses were observed in 16.3% of patients on RELA + NIVO vs. 14.2% on NIVO. Grade 3/4 treatment-related adverse events (TRAEs) were observed in 75 (21.1%) patients on RELA + NIVO and 40 (11.1%) on NIVO. There were four treatment-related deaths in the RELA + NIVO group and two in the NIVO group. TRAEs (any grade) leading to treatment discontinuation were observed in 54 (15.2%) patients on RELA + NIVO and 26 (7.2%) on NIVO. Conclusions: RELA + NIVO continued to demonstrate a PFS benefit vs. NIVO alone in patients with previously untreated metastatic or unresectable melanoma, consistent with the primary analysis. RELA + NIVO demonstrated a 20% reduction in risk of death and numerically improved OS rates vs. NIVO, although statistical significance was not reached for this secondary endpoint. ORR was higher with RELA + NIVO vs. NIVO. The safety profile of RELA + NIVO remained manageable with no new or unexpected safety signals. Clinical trial information: NCT03470922.
4
Wang, Lin, Zhen Ping Wu, Yu Cheng Jiang, Bing Ren, Jian Huang, Lin Jun Wang, Yi Ben Xia, and Ju Gao. "Impact of the Oxygen Content on the Electronic Properties in Epitaxial Thin Films of Electron-Doped La0.9Hf0.1MnO3." Advanced Materials Research 634-638 (January 2013): 2485–88. http://dx.doi.org/10.4028/www.scientific.net/amr.634-638.2485.
Abstract:
Thin films of perovskite manganite La0.9Hf0.1MnO3 (LHMO) have been grown on (100) SrTiO3 single-crystal substrates with different growth pressures by pulsed laser deposition. The different transport behaviors of films have been fitted by various models. The results clearly demonstrate that oxygen pressure is an efficient way to change the transport behaviors of LHMO films. All the transport behaviors observed in LHMO films can be better fitted by Mott’s variable range hopping model than the other two models.
5
Schenker, Michael, Mikhail Klochikhin, Dmitry Kirtbaya, Laurent Mortier, Martin Gschnell, Caroline Robert, Nicolas Meyer, et al. "Abstract PO-009: Phase 3 KEYNOTE-630 study of adjuvant pembrolizumab in high-risk locally advanced cutaneous squamous cell carcinoma." Clinical Cancer Research 29, no. 18_Supplement (September 15, 2023): PO—009—PO—009. http://dx.doi.org/10.1158/1557-3265.aacrahns23-po-009.
Abstract:
Abstract Introduction: Among patients with high-risk locally advanced (LA) cutaneous squamous cell carcinoma (cSCC), approximately 20% experience local disease recurrence within 5 years after standard-of-care surgical resection and adjuvant radiotherapy. Better treatment options are needed for patients who experience recurrence after surgery. The PD-1 inhibitors pembrolizumab (pembro) and cemiplimab have shown durable antitumor activity in advanced metastatic cSCC. The randomized, double-blind, placebo-controlled, phase 3 KEYNOTE-630 (NCT03833167) trial will be conducted to evaluate adjuvant pembro in patients with resectable, high-risk, LA cSCC. Materials and Methods: Eligible patients will have histologically confirmed LA cSCC as the primary site of malignancy and have undergone complete macroscopic resection of all disease with ≥1 high-risk feature: histologically involved nodal disease with extracapsular extension, with ≥1 lymph node >2 cm in diameter or ≥2 lymph nodes involved; any gross cortical bone, skull base, and/or skull base foramen invasion; any index tumor with ≥2 of the following: tumor ≥4 cm with >6-mm depth or invasion beyond subcutaneous fat, multifocal perineural invasion for nerves <0.1 mm in diameter (≥3 foci) or any involved nerve ≥0.1 mm in diameter, poor differentiation and/or sarcomatoid and/or spindle cell histology, recurrent disease (recurrence within 3 years in the previously treated area), or satellite lesions and/or in-transit metastases, lymphatic or vascular involvement. Patients must have received adequate postoperative dose of hypofractionated or conventional radiotherapy, including a BED EQD2 >48 Gy, have ECOG PS of 0 or 1, and completed adjuvant radiotherapy ≥4 and ≤16 weeks from randomization. Patients are required to provide tumor tissue for PD-L1 testing and have an ECOG PS of 0 or 1. Approximately 570 patients will be randomly assigned 1:1 to pembro 400 mg IV every 6 weeks or placebo for approximately 1 year (≤9 cycles). Stratification factors are extracapsular extension, cortical bone invasion, and prior systemic therapy (all, yes vs no). Patients receiving placebo may be eligible to cross over to receive pembro (≤18 cycles) if first biopsy-proven recurrence occurs within 5 years. In the pembro arm, eligible patients may receive pembro retreatment for up to 18 cycles. The primary end point is recurrence-free survival per investigator assessment with biopsy confirmation and secondary end points include overall survival, health-related quality of life, and safety. Computed tomography/magnetic resonance imaging of disease-involved areas and associated lymph nodes will be performed at screening and every 12 weeks until the end of year 2, then every 6 months until the end of 5 years. Adverse events will be monitored throughout the study and for 30 days after treatment end and graded per NCI CTCAE v4.0. Results: Recruitment is underway at sites in Asia, Australia, Europe, and North and South America. Conclusions: Results of KEYNOTE-630 will elucidate the role of adjuvant pembro in patients with high-risk, LA cSCC. Citation Format: Michael Schenker, Mikhail Klochikhin, Dmitry Kirtbaya, Laurent Mortier, Martin Gschnell, Caroline Robert, Nicolas Meyer, Lukas Flatz, Stephane Dalle, Marie Beylot-Barry, Thomas Eigentler, Rachel Kloss Silverman, Burak Gumuscu, Jianda Yuan, Aase Bratland. Phase 3 KEYNOTE-630 study of adjuvant pembrolizumab in high-risk locally advanced cutaneous squamous cell carcinoma [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Innovating through Basic, Clinical, and Translational Research; 2023 Jul 7-8; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2023;29(18_Suppl):Abstract nr PO-009.
6
Lee, Seok, Yoo-Jin Kim, Chang-Ki Min, Byung-Sik Cho, Sung-Yong Kim, Ki-Seong Eom, Heeje Kim, et al. "Predictive Potential of Minimal Residual Disease Level after the First Imatinib Cycle on the Outcome of Allogeneic Stem Cell Transplantation in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia." Blood 110, no. 11 (November 16, 2007): 1098. http://dx.doi.org/10.1182/blood.v110.11.1098.1098.
Abstract:
Abstract Purpose: Previously, we demonstrated the positive impact of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation (SCT) in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) (Blood2005;105:3449). Here, we analyzed for risk factors that affect transplantation outcome, and focused particularly on the prognostic relevance of minimal residual disease (MRD) during treatment course. Patients and Methods: Fifty-two consecutive adults with Ph-positive ALL who completed SCT following imatinib therapy were enrolled in this prospective study. MRD assessment was performed using real-time quantitative polymerase chain reaction. Results: Forty-three (87.8%) of the 49 evaluable patients showed a decrease in MRD after imatinib therapy. Molecular remission rates were 18.4% and 44.4% after the first and second imatinib cycles, respectively. Forty-eight (92.3%) of the 52 patients received SCT during first complete remission. With a median follow-up of 42 months after SCT, the actuarial 3-year relapse and disease-free survival (DFS) rates were 22.9% ± 6.6% and 67.3% ± 7.2%, respectively. An MRD level of ≥ 10−3 after the first imatinib cycle was found to be the most powerful predictor of relapse (47.5% ± 14.3% versus 11.4% ± 6.4%, P = .009) and DFS (45.0% ± 13.2% versus 80.9% ± 8.0%, P = .016). The presence of chronic graft-versus-host disease was also found to be associated with a lower relapse (5.3% ± 5.1% versus 37.6% ± 10.8%, P = .029) and better DFS (82.0% ± 9.5% versus 62.4% ± 10.8%, P = .039). Conclusion: In the setting of allogeneic SCT following imatinib therapy, prospective MRD monitoring may allow us to identify subgroups of Ph-positive ALL patients at high risk of relapse at an earlier treatment stage.
7
Yang, Jian Jun, Wen Hui Ma, Jie Yu, Xiu Hua Chen, Jie Xing, and Rui Li. "Preparation of La0.9SR0.1Ga0.8Mg0.2O3-δ Electrolyte Films Deposited by RF Magnetic Sputtering." Advanced Materials Research 634-638 (January 2013): 2550–54. http://dx.doi.org/10.4028/www.scientific.net/amr.634-638.2550.
Abstract:
La0.9Sr0.1Ga0.8Mg0.2O3-d (LSGM) electrolyte materials were synthesized using solid state reactions. The LSGM material film was deposited by radiofrequency magnetic sputtering on La0.7Sr0.3Cr0.5Mn0.5O3-d (LSCM) substrates. The analysis results show the films did not form but formed some “mountains” when deposited for 4 h. While the depositing time extended to 12 h, a dense and uniform film with perovskite phase was obtained, and the element amounts of the film were closed to those of the LSGM materials.
8
Semenova, Lioubov I., and Allan H. White. "Structural Systematics of Rare Earth Complexes. XVII Hydrated 1 : 1 Adducts of 2,2′:6′,2″-Terpyridine with the Lanthanoid(III) Bromides and Some Binuclear Hydroxy-Bridged Dimers." Australian Journal of Chemistry 52, no. 6 (1999): 539. http://dx.doi.org/10.1071/ch98048.
Abstract:
Room-temperature single-crystal X-ray structural characterizations are recorded for hydrated lan- thanoid(III) bromide/2,2′:6′,2″-terpyridine (tpy) (1 : 1) complexes, showing all to be ionic and of the form [(tpy)Ln(OH2)x]Br3.yH2O, where x and y are 6 and 1 for the isomorphous series Ln = La(-)Er (and intermediate members, by presumption), and 5 and various values for Ln = Tm, Yb, Lu. Crystals of [(tpy)Ln(OH2)6]Br3.H2O are monoclinic, P 21/c, a ≈ 8·5, b ≈ 18, c ≈ 16·3 Å, β ≈ 108°, Z = 4; for Ln = La, Er, conventional R values on |F| were 0·048, 0·080 for No 4027, 1347 ‘observed’ (I > 3σ(I)) diffractometer reflections respectively. The complex [(tpy)Tm(OH2)5]Br3.H2O is monoclinic, P 21/c, a 8·506(4), b 17·376(1), c 15·951(6) Å, β 106·87(3)°, Z = 4, (quasi-)isomorphous with the Ln = La-Er array, R 0·065 for No 2067. [(tpy)Yb(OH2)5]Br3.4H2O is triclinic, P 1, a 11·902(2), b 11·639(3), c 9·831(2) Å, α 98·92(2), β 106·84(2), γ 92·42(2)°, Z = 2, R 0·062 for No 3422, while [(tpy)Lu(OH2)5]Br3.H2O is monoclinic, P 21/n, a 13·635(8), b 9·022(5), c 19·03(1) Å, β 99·02(5)°, Z = 4, R 0·043 for No 3139. Despite a common N3LnO5 coordination sphere in the last three compounds, subtle differences are found in stereochemistry; in the N3LnO6 array, one of the outer water molecules becomes progressively detached as the lanthanoid radius contracts. Some tendency is found toward the end of the lanthanoid series toward the formation of di(hydroxy-bridged) neutral dimers, Ln(OH)Br2/tpy/H2O(1 : 1 : 8)(×2), [(tpy)(H2O)3Ln(µ-OH)2Ln(OH2)3(tpy)]Br4.10H2O, monoclinic, C 2/c, a ≈ 19·5, b ≈ 14·5, c ≈ 17·1 Å, β ≈ 92°, Z = 4 dimers, thus far defined by full determinations for the extrema Lu = Er, Lu (and Y), R 0·055, 0·043, (0·047) for No 3141, 4591, (2991) respectively; the dimer is disposed about a crystallographic 2 -axis. An Ln = Dy example, seemingly isomorphous, has also been characterized by cell determination.
9
Lipson, Evan J., Hussein Abdul-Hassan Tawbi, Dirk Schadendorf, Paolo Antonio Ascierto, Luis Matamala, Erika Castillo Gutiérrez, Piotr Rutkowski, et al. "Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047)." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 9503. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.9503.
Abstract:
9503 Background: Immune checkpoint inhibitor therapy has revolutionized the treatment of patients with advanced melanoma. However, novel combinations are needed to optimize the benefit-risk profile. Lymphocyte-activation gene 3 (LAG-3) regulates an immune checkpoint pathway, which inhibits T-cell activity, and is upregulated in many tumor types including melanoma. Relatlimab (RELA), a human IgG4 LAG-3-blocking antibody, restores effector function of exhausted T cells. RELA in combination with nivolumab (NIVO; anti-programmed death [PD]-1) modulates potentially synergistic immune checkpoint pathways and can enhance antitumor immune responses. RELATIVITY-047 is a global, randomized, double-blind, phase II/III study evaluating a novel immune checkpoint inhibitor combination of RELA+NIVO as a fixed-dose combination (FDC) treatment in first-line advanced melanoma. Methods: Patients with previously untreated advanced melanoma were randomized 1:1 to receive RELA 160 mg + NIVO 480 mg FDC intravenously (IV) every 4 weeks (Q4W) or NIVO monotherapy 480 mg IV Q4W, stratified by LAG-3 expression, programmed death ligand 1 expression, BRAF mutation status, and AJCC (v8) M stage. The primary endpoint was progression-free survival (PFS) per RECIST v1.1 as assessed by blinded independent central review. Secondary endpoints were overall survival and objective response rate. PFS in prespecified subgroups and safety were additional objectives. Results: 714 patients were randomized to RELA+NIVO FDC (n = 355) or NIVO (n = 359). Patient characteristics were well balanced between treatment groups. Median follow-up was 13.2 months. Median PFS in the RELA+NIVO FDC group (10.1 months [95% CI, 6.4–15.7]) was significantly longer than in the NIVO group (4.6 months [95% CI, 3.4–5.6]; hazard ratio, 0.75 [95% CI, 0.6–0.9]; P = 0.0055). PFS rates at 12 months were 47.7% (95% CI, 41.8–53.2) and 36.0% (95% CI, 30.5–41.6) for RELA+NIVO FDC and NIVO, respectively. PFS favored RELA+NIVO FDC across key prespecified subgroups. The incidence of grade 3/4 treatment-related adverse events (TRAEs) was higher in the RELA+NIVO FDC group (18.9%) versus NIVO (9.7%). There were 3 treatment-related deaths with RELA+NIVO FDC and 2 with NIVO. TRAEs (any grade) led to treatment discontinuation in 14.6% and 6.7% of patients in the RELA+NIVO FDC and NIVO groups, respectively. Conclusions: First-line treatment with RELA+NIVO FDC demonstrated a statistically significant PFS benefit compared to NIVO monotherapy in patients with advanced melanoma. RELA+NIVO FDC was well tolerated with a manageable safety profile and without unexpected safety signals. This is the first phase III study of a novel FDC to demonstrate a clinically meaningful benefit by dual inhibition of the LAG-3 and PD-1 pathways. Clinical trial information: NCT03470922.
10
Cao, Qin Bo, Shu Ming Weng, Chen Xiu Li, Shao Jun Bai, and Dan Liu. "Investigation on Beneficiation Strategy for Collophane." Advanced Materials Research 634-638 (January 2013): 3404–7. http://dx.doi.org/10.4028/www.scientific.net/amr.634-638.3404.
Abstract:
Phosphate being one of the three major nutrients required for agricultural plant growth usually presents as collophane in China. Since fine phosphate and other gauge minerals associate with each other and form intergrowth, the beneficiation of collophane is extremely difficult. In this paper, the flotation strategy for a low grade collophane ore from Guizhou province in China was studied in detail. Direct, reverse and direct-reverse combined flotation sheets were employed to collophane flotation. The results reveal that direct-reverse flotation is a suitable flotation flow sheet for this collophane ore. With direct-reverse flotation sheet, the grade of P2O5 in concentrate is 33%, which is improved by 3% comparing direct flotation and P2O5 recovery could achieve 80%. In addition, content of MgO decreased to 0.9%, which satisfied the requirement of wet-process phosphoric acid.
11
Wang, Zhi, Wei Zi Qin, Shuai Shuai Bao, Xiong Chen, Feng Lian Zhang, and Dong Sheng Li. "The Influences of Aerobic and Anaerobic Conditions on PHB and Glycerin Yields in the Process of Lignin Degradation by Pseudomonas stutzeri P156." Advanced Materials Research 634-638 (January 2013): 1170–74. http://dx.doi.org/10.4028/www.scientific.net/amr.634-638.1170.
Abstract:
The effects of aerobic and anaerobic conditions on polyhydroxybutyrate (PHB) and glycerin yields during the course of lignin degradation were studied with Pseudomonas stutzeri P156. The lignin degradation rate was 22.5% and 15%, respectively, under aerobic and anaerobic condition. However, the gradation rate/biomass (YL/X) was nearly no differences that diversified from 0.9% to 3%. In addition, the maximal anaerobic yield of PHB and glycerin yield was 0.42 g/g and 56.3 ug/ml, which was 176.6% and 36.7% higher than that under aerobic condition, respectively. Interestingly to point out, anaerobic lignin degradation rate was decreased by 33.3% relative to the aerobic one, but lignin content did decreased by 15% at the cost of higher yields of PHB and glycerin, which suggested biosyntheses of PHB and glycerin could balance the redox potential under anaerobic condition, facilitate lignin degradation by Pseudomonas stutzeri P156, persistently, and meet the process demands of straw-based anaerobic methane fermentation.
12
Miller, Kayla, and Trey A. Kellner. "276 Impact of pre-farrow feeding amount and timing on stillborn rate of sows." Journal of Animal Science 98, Supplement_3 (November 2, 2020): 100. http://dx.doi.org/10.1093/jas/skaa054.173.
Abstract:
Abstract Pre-farrowing feeding allowance and timing are often based on logistical ease instead of optimizing farrowing performance. The objective of this experiment was to decrease the stillborn rate via the amount and timing of feeding prior to farrowing. A total of 245 PIC 1050 (PIC, Inc., Hendersonville, TN) individually housed bred females were randomly allotted to 1 of 3 treatments on d 0. The 3 pre-farrow feeding treatments consisted of: 1) 2 meals of 0.9 kg fed at 630 h and 1530 h; 2) 1 meal of 1.8 kg fed at 630 h; and 3) 2 meals of 2.7 kg fed at 630 h and 1530 h. Dietary treatment commenced on entry into the farrowing crate and continued until they farrowed (ranged from d 2 to d 10). Data were analyzed using Proc MIXED (SAS 9.4; Cary, NC) with treatment as the main effect and sow as the experimental unit. Females having a litter with a total born ≤ 11 or ≥ 21 or did not consume their allotted feed were considered outliers and were removed from the statistical analysis. Feeding 2 meals of 0.9 kg per day trended to reduce stillborn rate compared to the other 2 pre-farrow feeding treatments (2 meals of 0.9 kg = 5.6%, 1 meal of 1.8 kg = 8.6%, 2 meals of 2.7 kg = 9.0%; P = 0.090). Pre-farrow feeding amount and time had no impact on total born or mummies (P ≥ 0.270). As a bonus, feeding small meals multiple times a day will reduce the farm’s overall feed cost compared to providing full feed access pre-farrow. In conclusion, implementation of a pre-farrowing feeding strategy is a vehicle that can be used to reduce the stillborn rate in commercial production.
13
Zhang, Zhi-Jun, Lin-qian Dimeng, Yan-wei Cao, Tong Zheng, Guan-yang Song, Yue Li, and Hui Zhang. "Predictors of Graft Failure After Primary Medial Patellofemoral Ligament Reconstruction." Orthopaedic Journal of Sports Medicine 10, no. 12 (December 1, 2022): 232596712211388. http://dx.doi.org/10.1177/23259671221138854.
Abstract:
Background: The tibiofemoral rotation angle has been found to be higher in patients with recurrent patellar dislocations (RPDs) than in healthy people; however, little is known about the clinical significance of this finding. Purpose: To determine whether an increased tibiofemoral rotation angle is associated with graft failure after primary medial patellofemoral ligament reconstruction (MPFL-R) and to investigate the role of the tibiofemoral rotation angle in predicting MPFL-R failure in patients with RPDs. Study Design: Case-control study; Level of evidence, 3. Methods: We retrospectively analyzed the records of 632 consecutive patients with clinically diagnosed RPDs from 2011 to 2018. Postoperative stress radiography of the patellofemoral joint was performed to identify whether the graft failed. After a review, 33 patients who showed MPFL-R failure were allocated to the failure group. They were matched 1:2 to 66 participants who underwent successful MPFL-R (control group). The cutoff value and area under the curve (AUC) of the tibiofemoral rotation angle for predicting graft failure after primary MPFL-R were determined, and the risk factors for MPFL-R failure were assessed by multivariate logistic regression analysis. Results: The tibiofemoral rotation angle was significantly higher in the failure group than in the control group (16.4° ± 5.6° vs 6.4° ± 4.5°, respectively; P < .001). The cutoff value of the tibiofemoral rotation angle for predicting graft failure was 12.3° (sensitivity, 81.8%; specificity, 89.4%; AUC, 0.920). Overall, 3 risk factors for MPFL-R failure were determined: excessive tibiofemoral rotation (≥12.3°) (odds ratio [OR], 13.159 [95% CI, 2.469-70.139]; P = .003), a preoperative high-grade J-sign (OR, 7.674 [95% CI, 1.232-47.809]; P = .029), and a femoral tunnel malposition (OR, 6.976 [95% CI, 1.077-45.187]; P = .042). Conclusion: In this study, excessive tibiofemoral rotation, a preoperative high-grade J-sign, and a femoral tunnel malposition were identified as risk factors for graft failure after primary MPFL-R in patients with RPDs. More importantly, excessive tibiofemoral rotation ( ≥ 12.3°) may predict the failure of primary MPFL-R, which can help surgeons easily identify high-risk patients of MPFL-R failure before surgery.
14
Berkowitz, Scott D., Charles W. Francis, Jennifer McElhattan, and Clifford W. Colwell. "Bleeding Indicators and Wound Complications with Ximelagatran and Warfarin after TKR: Findings from 3 Clinical Trials." Blood 104, no. 11 (November 16, 2004): 1771. http://dx.doi.org/10.1182/blood.v104.11.1771.1771.
Abstract:
Abstract Introduction: Prophylaxis of venous thromboembolism (VTE) in patients undergoing total knee replacement (TKR) most often entails anticoagulation, yet minimization of excessive postoperative bleeding and wound complications is critical to attain an excellent functional result. Ximelagatran (Exanta®, AstraZeneca), the first oral alternative to warfarin, has a rapid onset of action and requires no coagulation monitoring or dose adjustment. Three randomized, double-blind trials of VTE prophylaxis after TKR comparing ximelagatran 24 and 36 mg BID with well-controlled warfarin (target INR 2.5) were completed: Study 236 (n=680), EXULT A (n=2301), and EXULT B (n=2303). When administered for 7–12 days, ximelagatran 36 mg BID was superior to well-controlled warfarin, while 24 mg yielded numerically better but not statistically superior efficacy over warfarin. Adjudicated bleeding rates did not differ significantly. Objective: To assess the postoperative bleeding complications and overall surgical wound appearance during anticoagulation after TKR. Methods: Two comparison pools were created: 36-mg pool (ximelagatran 36 mg and corresponding warfarin groups from EXULT A and B) and 24-mg pool (ximelagatran 24 mg and corresponding warfarin groups from Study 236 and EXULT A). Bleeding indicators, i.e., postoperative wound drainage, bleeding index, and transfusion requirements, were compared. A prespecified subjective assessment of the surgical wound was performed on postoperative Day 3, end of treatment (Day 7–12), and at follow-up (4–6 weeks). If wound appearance was rated “worse than expected” at any time point, wound characteristics of swelling, drainage, erythema, and bleeding were assessed. Intra-articular bleeding, unusual bruising or hematoma, and bleeding requiring an intervention were also recorded. Results: 36-mg Pool (n=3810) 24-mg Pool (n=2178) Bleeding Indicators Ximelagatran Warfarin Ximelagatran Warfarin Post-op wound drainage, mean in mL (95% CI) 697 (675, 718) 704 (682, 725) 659 (632, 686) 654 (626, 682) Bleeding Index, mean (95% CI) 3.4 (3.3, 3.4) 3.3 (3.2, 3.4) 3.2 (3.1, 3.3) 3.1 (3.0, 3.2) Transfusions Unplanned, % of Pts 8.9 8.1 Not Assessed Not Assessed Total, % of Pts 33.5 33.6 37.6 34.3 Vol. Transfused/Pt, mean (95% CI) 630 mL (602, 659) 606 mL (578, 635) 1.7 U (1.6, 1.8) 1.7 U (1.6, 1.8) Overall wound appearance (worse than expected), % 9.2 8.7 8.9 8.2 Wound characteristics (worse than expected) Swelling, % 5.1 4.5 5.7 4.6 Drainage, % 3.6 2.4 2.7 1.8 Erythema, % 3.9 3.7 2.8 3.5 Bleeding, % 1.7 1.2 Not Assessed Not Assessed In the 36- and 24-mg pools the wound was assessed as “expected” or “better than expected” for ≥90% of the patients in the ximelagatran and warfarin groups. For the small number of patients with “worse than expected” wounds, the differences between the ximelagatran and warfarin groups were not statistically significant. Bleeding complications of the surgical wound, including intra-articular bleeding (<3.5%), unusual bruising or hematoma (<5.0%), and bleeding requiring an intervention (<0.9%), were few and comparable between treatment groups. Conclusions: Analysis of bleeding indicators and complications of the surgical wound revealed no significant differences between treatment groups, supporting the safety of 36 mg for all patients undergoing TKR.
15
Shen, Shi Han, Yu Yu Zhang, Tian Bin Li, and Qing Le Zeng. "Preparation and Water Absorbency of Superabsorbent Kaolin/PAA-AM Composite." Advanced Materials Research 634-638 (January 2013): 1968–76. http://dx.doi.org/10.4028/www.scientific.net/amr.634-638.1968.
Abstract:
In this paper, a novel superabsorbent composite material based on acrylic acid (AA), acrylic amide (AM) and inorganic kaolin was synthesized via solution polymerization in aqueous medium with N,N’-methylene bisacrylamide (MBA) as crosslinker and potassium persulfate (KPS) as initiator. The effects of water absorbency of the composite variables, such as neutralization, kaolin concentration and MBA concentration, on the water absorbency were systematically optimized. Evidence of compositing was obtained by a comparison of the Fourier transform infrared spectra of the initial reactants with that of the superabsorbent composites, and its complex structure was confirmed with scanning electron microscope. The water absorbing mechanism was also discussed. The results indicated that the superabsorbent composite material was successfully synthesized and the optimum reaction conditions were as follows: the neutralization degree was 80%, the dosage of kaolin, crosslinker and initiator were 4%, 0.11%, and 0.9% respectively and the mass ratio of AA and AM was 3∶2. The optimum absorbency of the superabsorbent composite material in distilled water could reach 815.6g/g.
16
Arif, Rifda Nur A., Abdurrahman Wahid, Ifa Hafifah, and Gia Eka Negara. "Effectiveness of Thermos to Maintain the Temperature of Ringer Lactate and Normal Saline 0.9% at AC Temperature 18˚C." Jurnal Ilmu Keperawatan (Journal of Nursing Science) 9, no. 2 (January 1, 2013): 204–11. http://dx.doi.org/10.21776/ub.jik.2021.009.02.8.
Abstract:
Hemorrhagic shock patients require fluid resuscitation, but extra efforts should be made to provide 39 C fluids to avoid hypothermia. One of the media to maintain temperature is a thermos. The purpose of this research is to identify whether the flasks can keep 39-degree crystalloid fluids at 18 degrees Celsius. This study used a pre-experimental method, with One-Shot Case Study type, 12 bottles of crystalloid liquid was warmed to 39°C, then put into 2 rice flasks, and temperature changes were measured for 6 hours at AC temperature 18˚C. The study was conducted on 30 November 2019. The findings show that temperatures in 6 bottles of RL liquid decreased by 6.8 -7.4 C and in 6 bottles of NS 0.9% liquid decreased by 5.3 - 6.4 C. Statistical results using the Mann-Whitney p-value is 0,000. It was concluded that there was a significant difference between changes in temperature of lactate Ringer's fluid and normal saline 0,9%. A thermos can maintain a temperature of 39˚C for about 1 hour and can prevent hypothermia from reaching 36˚C for about 3 hours.
17
Muth, Sebastian. "Anna Weirich: Sprachliche Verhältnisse und Restrukturierung sprachlicher Repertoires in der Republik Moldova, Peter Lang, Bern, 2018, 686 pp, Hb €101.90, ISBN 978-3-631-74371-3." Language Policy 19, no. 1 (June 19, 2019): 151–53. http://dx.doi.org/10.1007/s10993-019-09531-2.
18
เกิดอินทร์, มิตรา, กมลรัตน์ กิตติพิมพานนท์, and สุกัญญา ตันติประสพลาภ. "ความสัมพันธ์ระหว่างความรอบรู้ด้านสุขภาพ พฤติกรรมการดูแลตนเอง และผลลัพธ์ทางคลินิกของผู้ที่เป็นโรคไตเรื้อรังในหน่วยบริการปฐมภูมิ." Journal of Thailand Nursing and Midwifery Council 38, no. 02 (June 26, 2023): 64–76. http://dx.doi.org/10.60099/jtnmc.v38i02.262242.
Abstract:
บทนำ โรคไตเรื้อรังเป็นภาวะแทรกซ้อนที่สำคัญของโรคไม่ติดต่อเรื้อรัง การชะลอไตเสื่อมเป็นสิ่งสำคัญเพื่อป้องกัน การเกิดโรคไตเรื้อรังระยะสุดท้าย ความรอบรู้ด้านสุขภาพเป็นปัจจัยที่จะนำไปสู่พฤติกรรมที่พึงประสงค์ และเกิดผลลัพธ์ ทางคลินิกที่ดี วัตถุประสงค์การวิจัย 1) เพื่อศึกษาความรอบรู้ด้านสุขภาพในผู้ที่เป็นโรคไตเรื้อรังที่มารับบริการในหน่วยบริการ ปฐมภูมิ 2) เพื่อศึกษาพฤติกรรมการดูแลตนเองของผู้ที่เป็นโรคไตเรื้อรังที่มารับบริการในหน่วยบริการปฐมภูมิ และ 3) เพื่อศึกษาความสัมพันธ์ระหว่างความรอบรู้ด้านสุขภาพ พฤติกรรมการดูแลตนเอง อัตราการกรองของไต และโปรตีนในปัสสาวะของผู้ที่เป็นโรคไตเรื้อรังที่มารับบริการในหน่วยบริการปฐมภูมิ การออกแบบวิจัย การวิจัยเชิงพรรณนาวิเคราะห์ความสัมพันธ์ วิธีดำเนินการวิจัย ตัวอย่างเป็นผู้ที่เป็นโรคไตเรื้อรังระยะที่ 2 และ 3 ที่มารับบริการที่คลินิกโรคเรื้อรังของ โรงพยาบาลส่งเสริมสุขภาพตำบลจังหวัดนนทบุรีและนครปฐม จำนวน 108 คน คัดเลือกกลุ่มตัวอย่างแบบ เฉพาะเจาะจงตามเกณฑ์คัดเข้า เก็บข้อมูลโดยใช้แบบสอบถามข้อมูลส่วนบุคคล แบบประเมินความรอบรู้ด้านสุขภาพ แบบประเมินพฤติกรรมการดูแลตนเองของผู้ที่เป็นโรคไตเรื้อรัง และแบบบันทึกข้อมูลสุขภาพ วิเคราะห์ข้อมูล โดยสถิติบรรยาย สถิติสหสัมพันธ์แบบเพียร์สันและแบบสเปียร์แมน ผลการวิจัย พบว่า ผู้ที่เป็นโรคไตเรื้อรังมีความรอบรู้ด้านสุขภาพโดยรวมอยู่ในระดับดี เมื่อพิจารณารายด้าน พบว่า ผู้ที่เป็นโรคไตเรื้อรังมีทักษะการสื่อสาร การโต้ตอบ ซักถาม อยู่ในระดับพอใช้ และ การบอกต่ออยู่ในระดับน้อย พฤติกรรมการดูแลตนเองโดยรวมอยู่ในระดับดี ความรอบรู้ด้านสุขภาพมีความสัมพันธ์ทางบวกกับพฤติกรรมการ ดูแลตนเอง (rs = .580, p < .001) และอัตราการกรองของไต (rs = .215, p = .025) อย่างมีนัยสำคัญทางสถิติ แต่ไม่พบ ความสัมพันธ์ระหว่างความรอบรู้ด้านสุขภาพกับโปรตีนในปัสสาวะ (rs = -.047, p = .633) และพฤติกรรมการดูแล ตนเองกับอัตราการกรองของไต (r = .107, p = .271) และพฤติกรรมการดูแลตนเองกับโปรตีนในปัสสาวะ (rs = -.008, p = .931) ข้อเสนอแนะ การศึกษาครั้งนี้ชี้ให้เห็นความสำคัญของการส่งเสริมความรอบรู้ด้านสุขภาพอย่างต่อเนื่อง โดยเฉพาะ ทักษะด้านการสื่อสาร ซักถาม และแลกเปลี่ยนกับบุคลากรทางการแพทย์ และการบอกต่อ ซึ่งจะช่วยส่งเสริม ให้ผู้ที่เป็นโรคไตเรื้อรังเกิดพฤติกรรมการดูแลตนเองที่มีประสิทธิภาพ และชะลอไตเสื่อมได้
19
Gaki, Anna, G. Kakali, R. J. Wiglusz, W. Strek, and Grzegorz Paściak. "Synthesis, Characterization and Electrical Properties of Single Phase La0.9Sr0.1Ga0.8Mg0.2O3." Materials Science Forum 636-637 (January 2010): 874–79. http://dx.doi.org/10.4028/www.scientific.net/msf.636-637.874.
Abstract:
Single phase La0.9Sr0.1Ga0.8Mg0.2O3-δ (LSGM9182) was synthesized by a polymeric precursor route. The XRD pattern after calcination at 1300 °C for 6h indicates the formation of the perovskite without the presence of secondary phases. XRD, FTIR and TG-DTG measurements were used to examine the powder precursor as well as the intermediate and final products. SEM images indicated the small grain size of the final product. The conductivity of the sintered sample was examined by means of a.c. impedance spectroscopy and was found to be 9.10-2 S/cm at 800 °C similar to the typical value of LSGM materials.
20
Dadras, Siamak, Ezzeddin Mohajerani, Fereshteh Eftekhar, and Masoud Hosseini. "Different Photoresponses of Staphylococcus aureus and Pseudomonas aeruginosa to 514, 532, and 633 nm Low Level Lasers In Vitro." Current Microbiology 53, no. 4 (August 28, 2006): 282–86. http://dx.doi.org/10.1007/s00284-005-0490-3.
21
Effendy, Warren J. Grigsby, Robert D. Hart, Colin L. Raston, Brian W. Skelton, and Allan H. White. "Structural Characterization of Some Novel Oxidation Products of Triphenylstibine." Australian Journal of Chemistry 50, no. 6 (1997): 675. http://dx.doi.org/10.1071/c96042.
Abstract:
Room-temperature single-crystal X-ray structural characterizations of two oxidation products of triphenylstibine of the form XPh3SbOSbPh3X are recorded for X = Cl, NO3. ClPh3SbOSbPh3Cl is monoclinic, P 21/c, Z = 4 f.u., a 9·109(4), b 19·809(8), c 19·30(2) Å, β 109·27(5)°, conventional R on F being 0·038 for No 4431 ‘observe’ (I > 3σ(I)) independent reflections. In this complex, Sb-O-Sb is quasi-linear, 173·1(3)°, in contrast to the previously recorded benzene solvate, in which it is 139·0(3)°; in the nitrate, [(O2NO)Ph3SbOSbPh3(ONO2)], triclinic, P-1, Z = 2 f.u., a 15·609(5), b 13·238(4), c 10·140(2) Å, α 87·11(2), β 88·46(7), γ 72·93(2)°, R 0·036 for No 5275, it is also bent (137·0(2)°). The anionic substituent is opposed to the oxo bridge in the trigonal bipyramidal five-coordinate array about the metal in both complexes. A redetermination of the structure of Ph8Sb4O6 is recorded, presenting a non-disordered model in a triclinic P-1 cell, a 19·98(3), b 11·635(2), c 9·739(2) Å, α 92·28(1), β 98·98(1), γ 99·74(1)°, Z = 2 f.u., R 0·046 for No 3578. A new (‘β’) phase of triphenylstibine, crystallized from hexane/toluene is also recorded: monoclinic, P 21/c, a 15·386(8), b 11·304(5), c 19·078(8) Å, β11·64(4)°, Z = 8, R 0·045 for No 3393.
22
WOODWELL, GEORGE M. "Coastal Seas. The Conservation Challenge BY JOHN R. CLARK134 + ix pp., 24.4 × 17.2 × 0.9 cm, ISBN 0 632 04955 3 paperback, £14.95, Oxford, UK: Blackwell Science, 1998." Environmental Conservation 27, no. 2 (June 2000): 216–22. http://dx.doi.org/10.1017/s0376892900280235.
23
Matys, Jacek, Elżbieta Jaszczak, Rafał Flieger, Katarzyna Kostrzewska-Kaminiarz, Kinga Grzech-Leśniak, and Marzena Dominiak. "Effect of ozone and diode laser (635 nm) in reducing orthodontic pain in the maxillary arch—a randomized clinical controlled trial." Lasers in Medical Science 35, no. 2 (November 5, 2019): 487–96. http://dx.doi.org/10.1007/s10103-019-02896-0.
Abstract:
Abstract The effect of ozone, diode laser irradiation, and presence of teeth crowding/spacing on pain perception in orthodontic patient was tested. Overall, 76 patients [55 women and 21 men; age 35.1(6.4) years] who met the inclusion criteria participated in the study. Immediately after fixed orthodontic appliance placement, the patients were exposed to a pain relief treatment (one single session) using either 635-nm diode laser (SmartM, Lasotronix, Warsaw, Poland) or ozone therapy (OzoneDTA, Apoza, New Taipei City, Taiwan) by placing the handpieces in the area of each teeth apex and interdental papillae, from the maxillary right first molar to the maxillary left first molar. Subjects were divided into three groups: control group (G1, n = 26), ozone (G2, n = 26, exposed to ozone therapy, generator probe type 3, working time per point 5 s, 23 points, application time 1 min and 55 s), and laser group (G3, n = 25, exposed to continuous mode diode laser, 400 mW, handpiece diameter 8 mm, spot area 0.5024 cm2, power density per second 1.59 W/cm2, dose 2 J per point, time: 5 s per point, 23 points, total energy per session 46 J, application time 1 min and 55 s). The level of teeth crowding was assessed using the Lundstrom indicator. The patients received a questionnaire for pain assessment (the Numeric Rating Scale, NRS-11, grade level 0–10) and recorded at 7 time points (1 h, 6 h, and 1, 2, 3, 4, and 5 days ) after the fixed orthodontic appliance placement. The mean pain values for the diode laser, ozone, and control group were 3.6 (1.31) (95% CI, 2.95–4.25), 5.25 (3.37) (95% CI, 3.52–6.98), and 5.75 (2.40) (95% CI, 4.69–6.81), respectively. We observed lower pain values in the diode laser group compared to the control group (p = 0.0237). The use of ozone in this study did not result in significant pain reduction in comparison to control (p = 0.8040) and laser groups (p = 0.1029). There were no differences in pain perception between patients with crowded teeth and non-crowded teeth in each group (G1, p = 0.66, G2, p = 0.86, G3, p = 0.24). The use of 635-nm diode laser led to decreased pain perception; however, ozone and presence of teeth crowding/spacing did not affect the pain perception in orthodontic patients during the first 5 days after the fixed orthodontic appliance placement.
24
Chesney, P., L. Wessel-Beaver, G. Elmstrom, and D. Maynard. "624 PB 448 SHORT- AND LONG-VINE PUMPKINS INTERCROPPED WITH BEANS AND COWPEAS." HortScience 29, no. 5 (May 1994): 521f—522. http://dx.doi.org/10.21273/hortsci.29.5.521f.
Abstract:
Rows of tropical pumpkins (Cucurbita moschata) are typically spaced 3-4 m apart Rows fill in 8 to 10 weeks after planting, potentially allowing a short-seasoned intercrop to be planted. A long-vine cultivar (PRB-150) and a short vine genotype (FL-I25×I21 - winter planting; FL-I25 - fall) were planted 0.9 m within rows by 1.8 between rows in Lajas and Isabela, PR in winter and fall of 1993. Either beans, cowpeas or no intercrop were planted on the same date as the pumpkin maincrop. Legume plots were harvested both green-shelled and dry. Pumpkin canopy cover, yield, fruit number and size were the same in intercropped and non-intercropped plots These same traits varied significantly in short vs. long vine plots (short vine plots were lower yielding with smaller fruits and less canopy cover). Plots planted with the short-vine maincrop generally produced greater legume yields. Harvest of dry beans or cowpeas was nearly impossible in long vine plots since the canopy covered the legume plants at that stage. Intercropped green-shelled bean yields averaged 800 kg/ha. Such a yield would add substantially to the income of the pumpkin maincrop.
25
Alcántara-González, Javier, Leticia Calzado-Villarreal, Maria Elena Sánchez-Largo, Marta Andreu-Barasoain, and Marta Ruano-Del Salado. "Recalcitrant viral warts treated with photodynamic therapy methyl aminolevulinate and red light (630 nm): a case series of 51 patients." Lasers in Medical Science 35, no. 1 (June 17, 2019): 229–31. http://dx.doi.org/10.1007/s10103-019-02823-3.
26
Gudieva, I. R., B. M. Maliev, N. V. Kobesov, O. Z. Basieva, and S. A. Sterlikov. "The Incidence of Comorbidities in New Adult Tuberculosis Cases." Tuberculosis and Lung Diseases 101, no. 3 (July 4, 2023): 21–26. http://dx.doi.org/10.58838/2075-1230-2023-101-3-21-26.
Abstract:
The objective: to determine the potential impact of particular nosologies and their groups on the risk of developing tuberculosis.Subjects and Methods. The incidence of particular nosologies and their groups standardized by gender and age in new tuberculosis cases detected in 2020 was compared to the general incidence of those nosologies among population of RNO-Alania. Relative risk (RR) and statistical significance of differences (p) were determined.Results. RR of type I diabetes mellitus (DM) in tuberculosis patients to the overall incidence of the entire population was 9,5 (p<0,001); RR of viral hepatitis – 6,4 (p<0,001); mental disorders – 3.2 (p<0,001); type II DM – 2,6 (p<0,001); chronic nonspecific lung diseases (CNLD) – 2,3 (p=0,005). There was no excess of RR for digestive diseases (RR=0,9; p=0,9). The role of genitourinary diseases could not be verified due to the lack of observations.
27
Nino, Akihiro, Takashi Sekine, Kazuhisa Sugawara, Shigeaki Sugiyama, and Hitoshi Taimatsu. "Effect of Added Cr3C2 on the Microstructure and Mechanical Properties of WC–SiC Ceramics." Key Engineering Materials 656-657 (July 2015): 33–38. http://dx.doi.org/10.4028/www.scientific.net/kem.656-657.33.
Abstract:
WC–20 mol% SiC ceramics with added Cr3C2 were sintered at 1600°C with a resistance-heated hot-pressing machine. Dense WC–SiC ceramics containing 0.1–0.9 mol% Cr3C2 were obtained. Above 1.2 mol% Cr3C2, the relative density decreased with increasing Cr3C2 content. A small amount of a Nowotny-phase type (Mo5Si3C-type) product was formed by the addition of Cr3C2, and no Cr3C2-based solid solution was found. The WC–20 mol% SiC–Cr3C2 ceramics had very fine equiaxed granular WC grains because of inhibited grain growth of WC. The Young’s modulus of the WC–20 mol% SiC–Cr3C2 ceramics decreased with increasing Cr3C2 content because Cr3C2 has a much lower Young’s modulus than WC. Cr3C2 addition below 0.9 mol% increased the Vickers hardness from 20.9 to 23.0 GPa, but a larger added amount reduced the Vickers hardness. The hardness of the WC–20 mol% SiC–Cr3C2 ceramics and the WC grain size obeyed a Hall–Petch-like relationship, suggesting that the hardness was strongly controlled by the WC grain size. A higher fracture toughness, 6.4 MPa m1/2, was obtained for the ceramics containing a small amount of Cr3C2 than for the binder-free WC. The addition of 0.1–0.3 mol% Cr3C2 improved the fracture toughness without reducing the hardness.
28
Zhang, Liang, Mariano Méndez, Federico García, Yuexin Zhang, Ruican Ma, Diego Altamirano, Zi-Xu Yang, et al. "Type-A quasi-periodic oscillation in the black hole transient MAXI J1348−630." Monthly Notices of the Royal Astronomical Society 526, no. 3 (October 9, 2023): 3944–50. http://dx.doi.org/10.1093/mnras/stad3062.
Abstract:
ABSTRACT We present a detailed analysis of the spectral and timing characteristics of a 7-Hz type-A quasi-periodic oscillation (QPO) detected in NICER observations of the black hole X-ray binary MAXI J1348−630 during its high-soft state. The QPO is broad and weak, with an integrated fractional rms amplitude of 0.9 per cent in the 0.5–10 keV band. Thanks to the large effective area of NICER, combined with the high flux of the source and a relatively long accumulative exposure time, we construct the first rms and phase-lag spectra for a type-A QPO. Our analysis reveals that the fractional rms amplitude of the QPO increases with energy from below 1 per cent at 1 keV to ∼3 per cent at 6 keV. The shape of the QPO spectrum is similar to that of the Comptonized component, suggesting that the Comptonized region is driving the variability. The phase lags at the QPO frequency are always soft taking the lowest energy as reference. By jointly fitting the time-averaged spectrum of the source and the rms and phase-lag spectra of the QPO with the time-dependent Comptonization model vkompthdk, we find that the radiative properties of the type-A QPO can be explained by a vertically extended Comptonized region with a size of ∼2300 km.
29
Jithesh, V., Ranjeev Misra, Bari Maqbool, and Gitika Mall. "Broad-band spectral and timing properties of MAXI J1348–630 using AstroSat and NICER observations." Monthly Notices of the Royal Astronomical Society 505, no. 1 (May 10, 2021): 713–25. http://dx.doi.org/10.1093/mnras/stab1307.
Abstract:
ABSTRACT We present broad-band X-ray spectral-timing analysis of the new Galactic X-ray transient MAXI J1348–630 using five simultaneous AstroSat and NICER observations. Spectral analysis using AstroSat data identify the source to be in the soft state for the first three observations and in a faint and bright hard state for the next two. Quasi-periodic oscillations at ∼0.9 and ∼6.9 Hz, belonging to the type-C and type-A class are detected. In the soft state, the power density spectra are substantially lower (by a factor >5) for the NICER (0.5–12 keV) band compared to the AstroSat/LAXPC (3–80 keV) one, confirming that the disc is significantly less variable than the Comptonization component. For the first time, energy-dependent fractional rms and time lag in the 0.5–80 keV energy band was measured at different Fourier frequencies, using the bright hard state observation. Hard time lag is detected for the bright hard state, while the faint one shows evidence for soft lag. A single-zone propagation model fits the LAXPC results in the energy band 3–80 keV with parameters similar to those obtained for Cygnus X–1 and MAXI J1820+070. Extending the model to lower energies, reveals qualitative similarities but having quantitative differences with the NICER results. These discrepancies could be because the NICER and AstroSat data are not strictly simultaneous and because the simple propagation model does not take into account disc emission. The results highlight the need for more joint coordinated observations of such systems by NICER and AstroSat.
30
Bodkin, Stephan G., Margaret H. Rutherford, David R. Diduch, Stephen F. Brockmeier, and Joe M. Hart. "How Much Time Is Needed Between Serial “Return to Play” Assessments to Achieve Clinically Important Strength Gains in Patients Recovering From Anterior Cruciate Ligament Reconstruction?" American Journal of Sports Medicine 48, no. 1 (November 22, 2019): 70–77. http://dx.doi.org/10.1177/0363546519886291.
Abstract:
Background: Pass rates for return-to-play evaluations are alarmingly low for patients after anterior cruciate ligament reconstruction (ACLR). Since timing of return to play is a complicated decision, it is important that patients be given optimal time to realize meaningful improvements in strength that warrant additional testing. Purpose: To (1) compare outcomes among patients assessed at different time points after ACLR, (2) determine strength gains indicative of improvements in subjective function, and (3) determine the amount of time necessary to achieve meaningful strength gains. Study Design: Cross-sectional/case-control study; Level of evidence, 3. Methods: A total of 293 patients participated in the study after ACLR (mean ± SD, 23.2 ± 10.1 years old; n = 142 female participants; 6.4 ± 0.9 months after ACLR). Participants were stratified on the month of their evaluation after ACLR: 5 to 6 months (n = 122), 6 to 7 months (n = 102), 7 to 8 months (n = 43), and 8 to 9 months (n = 26). The International Knee Documentation Committee (IKDC) subjective form and knee extensor and flexor torque and symmetry, as assessed through an isokinetic dynamometer, were compared among groups. Forty patients (20 female participants, 20.4 ± 7.1 years old) were referred for subsequent testing (2.14 ± 0.78 months after initial visit). Subjective improvement between visits was defined as a ≥9-point change of the IKDC score. Thresholds of knee extensor torque and symmetry indicative of subjective improvement and the time between assessments needed to achieve these strength improvements were determined. Results: Patients between 5 and 6 months (IKDC, 79.7; interquartile range [IQR], 70.1-88.5) had lower subjective function compared to patients between 6 and 7 months (IKDC, 83.9; IQR, 74.5-92.0; P = .019) and 8 and 9 months after ACLR (IKDC, 89.1; IQR 75.8-92.3; P = .026). Patients between 5 and 6 months (1.41 N·m/kg; IQR, 1.16-1.73 N·m/kg]) had lower knee extensor torque compared to patients 6 and 7 months (1.59 N·m/kg; IQR, 1.23-1.95 N·m/kg; P = .013) and 7 and 8 months after ACLR (1.62 N·m/kg; IQR, 1.30-1.86 N·m/kg; P = .046). Patients between 5 and 6 months (66.4%; IQR, 54.2-78.6) had lower symmetry compared to patients between 6 and 7 months (71.8%; IQR,61.1-82.9; P = .019) and 8 and 9 months afterACLR (75.2%; IQR, 66.6-87.7; P = .014). Of the 40 patients that completed follow-up assessments, an increase in knee extensor torque of 0.22 N·m/kg and symmetry of 5.75% discriminated patients that achieved subjective improvement. A period of 1.97 months between assessments discriminated those that achieved the established symmetry threshold. Conclusion: Patients demonstrate increasing subjective and quadriceps function when tested at later time points from surgery; however, the observed values are low, suggesting that at 9 months patients are demonstrating deficits that may be improving. Approximately 2 months is needed to observe clinically meaningful improvements.
31
Michaeli, Thomas, Niklas Thilo, Daniel Tobias Michaeli, Helge Beth, Friederike Hoffmann, Melanie Janning, Erik Engel, Gunter Schuch, and Sonja Loges. "Association of SARS-CoV-2 vaccinations and personal protective measures with seroconversion and risk of infection in a large real-world cohort of patients with cancer." Journal of Clinical Oncology 41, no. 16_suppl (June 1, 2023): e18835-e18835. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e18835.
Abstract:
e18835 Background: Longitudinal data assessing seroconversion after different doses of SARS-CoV-2 vaccines and the role of personal protective measures to prevent COVID-19 infections remain scarce. This is the first study to evaluate the association between SARS-CoV-2 vaccination, tumor subgroups, cancer treatment, and personal protective measures with antibody titers as well as COVID-19 infections in a real-world cohort of cancer patients. Methods: This retrospective cohort study enrolled 633 adult patients all treated at a large oncology clinic in Hamburg (Germany) from January 2020 to July 2022. Data about demographics, cancer treatment, vaccinations, SARS-CoV-2-IgG antibody titers, personal protective measures, COVID-19 infections and infection-associated symptoms were reported in the patients’ health records. Primary outcomes were: (i) patients’ SARS-CoV-2-IgG antibody concentrations and (ii) COVID-19 infections. A multivariate regression model, reporting adjusted odds ratios (AOR), evaluated the association between collected variables and seroconversion rates after SARS-CoV-2 vaccination. A time-varying Kaplan-Meier survival analysis explored the association between the collected variables and the risk of infection. Results: Of 633 cancer patients, 52% had solid tumors and 48 % hematologic malignancies. Seroconversion was significantly associated with the number of vaccine doses, prior infections (AOR: 1.91, 95%CI: 1.01-3.60, p = .045), hematologic cancers (AOR: 0.58, 95%CI: 0.40-0.85, p = .005), and treatment with CD20/38 inhibitors or immune checkpoint inhibitors (ICI) (AOR: 0.58, 95%CI: 0.35-0.95, p = .030). 120 patients (19%) had a COVID-19 infection with 77% experiencing exhaustion, 67% fever, 62% rhinitis, 62% headache, 56% sore throat, and 48% a non-productive cough. Patients on anti-cancer treatments had a 63% (HR: 1.63, 95%CI: 1.04-2.57, p = .034) higher risk of infection. The risk of infection was 43% (AOR: 0.57, 95%CI: 0.38-0.85, p = .006) and 87% (AOR: 0.23, 95%CI: 0.11-0.47, p < .001) lower among patients with 2 and ≥3 vaccine doses, respectively. Wearing FFP2 masks (AOR: 0.74, 95%CI: 0.56-0.99, p = .046) and reducing social contacts (AOR: 0.81, 95%CI: 0.65-0.99, p = .042) were associated with a lower risk of infection, but this was not the case for wearing surgical masks or using a “Corona warning” app. Conclusions: In this study, SARS-CoV-2 vaccination was associated with lower infection rates in cancer patients. However, certain subgroups remained at an increased risk of infection despite vaccination, e.g. patients receiving CD20/38 or ICI anti-cancer therapy with hematologic cancers. More than two vaccine doses, FFP2 masks, and social distancing led to lower infection rates. These findings are instrumental in guiding recommendations for preventing COVID-19 infections in cancer patients.
32
von Pawel, Joachim, Robert Jotte, David R. Spigel, Mary E. R. O'Brien, Mark A. Socinski, Jörg Mezger, Martin Steins, et al. "Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer." Journal of Clinical Oncology 32, no. 35 (December 10, 2014): 4012–19. http://dx.doi.org/10.1200/jco.2013.54.5392.
Abstract:
Purpose Amrubicin, a third-generation anthracycline and potent topoisomerase II inhibitor, showed promising activity in small-cell lung cancer (SCLC) in phase II trials. This phase III trial compared the safety and efficacy of amrubicin versus topotecan as second-line treatment for SCLC. Patients and Methods A total of 637 patients with refractory or sensitive SCLC were randomly assigned at a ratio of 2:1 to 21-day cycles of amrubicin 40 mg/m2 intravenously (IV) on days 1 to 3 or topotecan 1.5 mg/m2 IV on days 1 to 5. Primary end point was overall survival (OS); secondary end points included overall response rate (ORR), progression-free survival (PFS), and safety. Results Median OS was 7.5 months with amrubicin versus 7.8 months with topotecan (hazard ratio [HR], 0.880; P = .170); in refractory patients, median OS was 6.2 and 5.7 months, respectively (HR, 0.77; P = .047). Median PFS was 4.1 months with amrubicin and 3.5 months with topotecan (HR, 0.802; P = .018). ORR was 31.1% with amrubicin and 16.9% with topotecan (odds ratio, 2.223; P < .001). Grade ≥ 3 treatment-emergent adverse events in the amrubicin and topotecan arms were: neutropenia (41% v 54%; P = .004), thrombocytopenia (21% v 54%; P < .001), anemia (16% v 31%; P < .001), infections (16% v 10%; P = .043), febrile neutropenia (10% v 3%; P = .003), and cardiac disorders (5% v 5%; P = .759); transfusion rates were 32% and 53% (P < .001), respectively. NQO1 polymorphisms did not influence safety outcomes. Conclusion Amrubicin did not improve survival when compared with topotecan in the second-line treatment of patients with SCLC. OS did not differ significantly between treatment groups, although an improvement in OS was noted in patients with refractory disease treated with amrubicin.
33
Behrend, Christian. "Gründlich, aber nebenwirkungsreich." InFo Hämatologie + Onkologie 22, no. 1-2 (February 2019): 38. http://dx.doi.org/10.1007/s15004-019-6394-3.
34
Carbonell, Elvira, Elvira Costell, and Luís Durán. "Evaluation of Various Methods for Measurement of Pectin Content in Jam." Journal of AOAC INTERNATIONAL 72, no. 4 (July 1, 1989): 689–93. http://dx.doi.org/10.1093/jaoac/72.4.689.
Abstract:
Abstract Suitability, precision, and accuracy of 3 colorimetric methods to measure pectin content in fruit jams are examined. The methods resolve non-uronide interferences in different ways: (1) with 3,5-dimethylphenol colorimetric reagent, and absorbance differences measured at 450 and 400 nm; (2) with m-hydroxydiphenyl colorimetric reagent, and numeric correction of sample blank to compensate for interferences; and (3) with m-hydroxydiphenyl colorimetric reagent and removal of interferences by purification of sample pectins. The 3,5-dimethylphenol method is not suitable when fructose is present. Precision and accuracy of the second method are not satisfactory because sugar/pectin ratio in jam samples is very high. The third method is recommended because the precision (0.9% < CV < 6.4%) is good and recovery is nearly 100%.
35
Mursell, Gordon. "The mystical tradition and the Carthusians. Internationaler Kongress vom 20. bis zum 23. September 1995 anlasslich der Emeritierung des Herausgebers der Analecta Cartusiana. 8 vols. Edited by James Hogg. (Analecta Cartusiana, 130.) Pp. vi + 172; iii + 167; iv + 171; 108; 167; 433; iii + 434–631; iii9 + 632–909. Universität Salzburg: Institut für Anglistik und Amerikanistik, 1995. 3 7052 0144 9; 3 7052 0448 3; 3 7052 0449 1; 3 7052 0447 7; 0 7052 0448 5; 3 7052 0393 2; 3 7052 0449 3; 3 7052 0394 0 - Dionysius der Kartäuser. Einführung in Werk und Gedankenwelt. By Dirk Wasserman. (Analecta Cartusiana, 133.) Pp. v + 288; Universität Salzburg: Institut für Anglistik und Amerikanistik, 1996. 3 7052 0638 9." Journal of Ecclesiastical History 48, no. 4 (October 1997): 758–60. http://dx.doi.org/10.1017/s0022046900013762.
36
Chuchalin, A. G., S. N. Avdeev, A. V. Bezlepko, V. A. Dobrich, V. A. Ignatiev, I. V. Leshenko, T. I. Martinenko, et al. "Almitrine bismesylate treatment in patient with chronic obstructive pulmonary disease and moderate chronic respiratory failure. Open prospective multicentre trial." PULMONOLOGIYA, no. 2 (April 28, 2005): 92–100. http://dx.doi.org/10.18093/0869-0189-2005-0-2-92-100.
Abstract:
The efficacy and safety of almitrine bismesylate treatment was assessed in COPD patients in 6 month open prospective multicentre trial. 77 COPD patients with moderate hypoxemia were included (males / females — 57 / 20, mean age 63.2 ± 9.7 years; mean FEV1 0.95 ± 0.38 L, mean PaO2 63.3 ± 5.4 mmHg, mean PaСO2 44.1 ± 7.3 mmHg). We used an intermittent regime of almitrine administration: 1 mg / kg / day, for 3 months, then a "window" of 1 month, and again active therapy for 2 months. Almitrine therapy resulted in improvement of РаО2: rise after 1 month to 71.5 ± 10.6 mmHg, after 3 month — to 70.3 ± 8.3 mmHg, and after 6 month — to 72.5 ± 14.2 mmHg (р < 0.001). There was a significant fall in dyspnea during daily life activities (MRC score): from 3.5 ± 0.9 to 3.0 ± 0.9 (1 month), 2.8 ± 0.9 (3 month), 2.6 ± 0.7 (6 month) (р < 0.001). The distance during 6 minute walk test (6 MWT) increased from 334 ± 108 m to 371 ± 101 m (1 month), 377 ± 88 m (3 month), 398 ± 104 m (6 month) (р < 0.001). The levels of desaturation and Borg dyspnea score during 6 MWT significantly decreased (both р < 0.001). During almitrine treatment an improvement in almost all domains of SF 36 quality of life questionnaire was noted. 58 COPD patients completed the study. The most common adverse effects were parasthesia (6.4 %) and worsening of dyspnea (5 %), pulmonary artery pressure did not change during study. Conclusions: almitrine treatment in COPD patients with moderate hypoxemia resulted in improvement of arterial oxygenation, reduction of dyspnea during daily life activities and exercise, increase of physical capacity and improvement of health related quality of life.
37
Costa, Adrienny T. R., Francisco C. F. Lobato, Vera L. V. Abreu, Ronnie A. Assis, Ronaldo Reis, and Francisco A. Uzal. "Serotyping and evaluation of the virulence in mice of Streptococcus suis strains isolated from diseased pigs." Revista do Instituto de Medicina Tropical de São Paulo 47, no. 2 (April 2005): 113–15. http://dx.doi.org/10.1590/s0036-46652005000200012.
Abstract:
A total of 110 strains of Streptococcus suis, isolated from diseased pigs in Brazil were serotyped and analyzed for virulence. Serotyping of the strains resulted in the following classification: 42 strains of serotype 2 (38.2%), 10 strains of serotype 14 (9.1%), seven strains of serotype 9 (6.4%), three strains each of serotype 7 and 11 (2.7%), two strains each of serotype 1 and 8 (1.8%) and one strain each of serotypes ½, 3, 5, 6 and 10 (0.9%). Cross reactions among serotypes 1, 14 and 7 were observed in 21 strains (19.1%). Only 41.9% of the strains were lethal for mice using the pathogenicity test.
38
Griffiths, H., V. Brennan, J. Lea, C. Bunch, M. Lee, and H. Chapel. "Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors." Blood 73, no. 2 (February 1, 1989): 366–68. http://dx.doi.org/10.1182/blood.v73.2.366.366.
Abstract:
Abstract A randomized crossover study of prophylactic immunoglobulin (IgG) therapy was performed in patients with chronic lymphocytic leukaemia (CLL) or non-Hodgkin's lymphoma (NHL). Twelve patients with hypogammaglobulinemia or a history of recurrent infections received infusions of IgG or placebo intravenously (IV) every 3 weeks for 1 year. They were then switched to the alternative preparation for another year. The number of serious bacterial infections was significantly less (P = .001; Mainland's cross-over method) in the months in which patients received IgG. Serious bacterial infections showed a trend to be associated with an IgG level less than 6.4 g/L (P = .046; Fisher's exact test).
39
Griffiths, H., V. Brennan, J. Lea, C. Bunch, M. Lee, and H. Chapel. "Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors." Blood 73, no. 2 (February 1, 1989): 366–68. http://dx.doi.org/10.1182/blood.v73.2.366.bloodjournal732366.
Abstract:
A randomized crossover study of prophylactic immunoglobulin (IgG) therapy was performed in patients with chronic lymphocytic leukaemia (CLL) or non-Hodgkin's lymphoma (NHL). Twelve patients with hypogammaglobulinemia or a history of recurrent infections received infusions of IgG or placebo intravenously (IV) every 3 weeks for 1 year. They were then switched to the alternative preparation for another year. The number of serious bacterial infections was significantly less (P = .001; Mainland's cross-over method) in the months in which patients received IgG. Serious bacterial infections showed a trend to be associated with an IgG level less than 6.4 g/L (P = .046; Fisher's exact test).
40
Ateudjieu, Jérôme, Ketina Hirma Tchio-Nighie, André Pascal Goura, Martin Yakum Ndinakie, Miltiade Dieffi Tchifou, Lapia Amada, Marcelin Tsafack, et al. "Tracking Demographic Movements and Immunization Status to Improve Children’s Access to Immunization: Field-Based Randomized Controlled Trial." JMIR Public Health and Surveillance 8, no. 3 (March 1, 2022): e32213. http://dx.doi.org/10.2196/32213.
Abstract:
Background Countries’ Expanded Program on Immunization (EPI) contribute to the reduction of mortality and morbidity, but access to these vaccines remains limited in most low-income countries. Objective We aim to assess whether involving community volunteers (CVs) to track children’s vaccination status and demographic movements and using recorded data to plan catch-up immunization sessions can improve children’s vaccination timeliness, completeness, and coverage. Methods This was a field-based randomized controlled trial and communities of the Foumban health district in West Cameroon were allocated to intervention or control groups. In the intervention group, a CV per community was trained to visit households monthly for a year to assess and record in a register, details of EPI-targeted children, their demographic movements and immunization status. The scanned recorded pages were sent to the health center immunization team through WhatsApp and used to organize monthly community catch-up immunization sessions. In the control group, EPI vaccination sessions were routinely conducted. Surveys were conducted at 6 and 12 months from the beginning of the intervention in both study groups to assess and compare immunization timeliness, coverage, and completeness. Results Overall, 30 buildings per cluster were surveyed at midline and endline. Of the 633 and 729 visited households in the intervention group at midline and endline, 630 (99.5%) and 718 (98.4%), respectively, consented to participate. In the control group, 507 and 651 households were visited and 505 (99.6%) and 636 (97.7%), respectively, consented to participate. At 12 months intervention, the month one timeliness of bacille Calmette–Guerin (BCG) vaccine did not increase in the intervention group compared with the control group for the age groups 0-11 months (adjusted odds ratio [aOR] 1.1, 95% CI 0.7-1.8) and 0-59 months (aOR 1.1, 95% CI 0.9-1.4), and significantly increased for the first-year BCG vaccine administration for the age group 0-23 months (aOR 1.5, 95% CI 1.1-2.2). The coverage of diphtheria-pertussis-tetanus and hepatitis B+Hemophilus influenzae type B (DPT-Hi +Hb) dose 3 (aOR 2.0, 95% CI 1.5-2.7) and of DPT-Hi+Hb dose 1 (aOR 1.8, 95% CI 1.4-2.4) vaccines increased significantly in the intervention group compared with the control group in the age groups 12-59 months and 12-23 months, respectively. Specific (DPT-Hi+Hb dose 1 to DPT-Hi+Hb dose 3: aOR 1.9, 95% CI 1.4-2.6) and general (BCG to measles: aOR 1.5, 95% CI 1.1-2.1) vaccine completeness increased significantly in the intervention group compared with the control group. Conclusions Findings support that involving CVs to track children’s vaccination status and demographic movements and using recorded data to plan catch-up immunization sessions improve children’s vaccination timeliness, completeness, and coverage. This strategy should be adopted to improve access to vaccination for EPI target populations and the consistency verified in other contexts. Trial Registration Pan African Clinical Trials Registry PACTR201808527428720; https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=3548
41
Asken, Breton M., Russell M. Bauer, Kevin M. Guskiewicz, Michael A. McCrea, Julianne D. Schmidt, Christopher C. Giza, Aliyah R. Snyder, et al. "Immediate Removal From Activity After Sport-Related Concussion Is Associated With Shorter Clinical Recovery and Less Severe Symptoms in Collegiate Student-Athletes." American Journal of Sports Medicine 46, no. 6 (March 20, 2018): 1465–74. http://dx.doi.org/10.1177/0363546518757984.
Abstract:
Background: Timely removal from activity after concussion symptoms remains problematic despite heightened awareness. Previous studies indicated potential adverse effects of continuing to participate in physical activity immediately after sustaining a concussion. Hypothesis/Purpose: The purpose was to determine the effect of timing of removal from play after concussion on clinical outcomes. It was hypothesized that immediate removal from activity after sport-related concussion (SRC) would be associated with less time missed from sport, a shorter symptomatic period, and better outcomes on acute clinical measures. Study Design: Cohort study; Level of evidence, 3. Methods: Data were reported from the National Collegiate Athletic Association and Department of Defense Grand Alliance: Concussion Awareness, Research, and Education (CARE) Consortium. Participants with 506 diagnosed SRCs from 18 sports and 25 institutions and military service academies were analyzed and classified as either immediate removal from activity (I-RFA) or delayed removal from activity (D-RFA). Outcomes of interest included time missed from sport attributed to their SRC, symptom duration, and clinical assessment scores. Results: There were 322 participants (63.6%) characterized as D-RFA. I-RFA status was associated with significantly less time missed from sport ( R2 change = .022-.024, P < .001 to P = .001) and shorter symptom duration ( R2 change = .044-.046, P < .001 [all imputations]) while controlling for other SRC recovery modifiers. These athletes missed approximately 3 fewer days from sport participation. I-RFA athletes had significantly less severe acute SRC symptoms and were at lower risk of recovery taking ≥14 days (relative risk = .614, P < .001, small-medium effect size) and ≥21 days (relative risk = .534, P = .010, small effect size). Conclusion: I-RFA is a protective factor associated with less severe acute symptoms and shorter recovery after SRC. Conveying this message to athletes, coaches, and others involved in the care of athletes may promote timely injury reporting.
42
Parada, Belmiro, Flávio Reis, Raquel Cerejo, Patrícia Garrido, José Sereno, Maria Xavier-Cunha, Paula Neto, Alfredo Mota, Arnaldo Figueiredo, and Frederico Teixeira. "Omega-3 Fatty Acids Inhibit Tumor Growth in a Rat Model of Bladder Cancer." BioMed Research International 2013 (2013): 1–11. http://dx.doi.org/10.1155/2013/368178.
Abstract:
Omega-3 (ω-3) fatty acids have been tested on prevention and treatment of several cancer types, but the efficacy on “in vivo” bladder cancer has not been analyzed yet. This study aimed at evaluating the chemopreventive efficacy of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) mixture in an animal model of bladder cancer. Forty-four male Wistar rats were divided into 4 groups during a 20-week protocol: control; carcinogen—N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN);ω-3 (DHA + EPA); andω-3 + BBN. BBN andω-3 were given during the initial 8 weeks. At week 20 blood and bladder were collected and checked for the presence of urothelium lesions and tumors, markers of inflammation, proliferation, and redox status. Incidence of bladder carcinoma was, control (0%),ω-3 (0%), BBN (65%), andω-3 + BBN (62.5%). Theω-3 + BBN group had no infiltrative tumors or carcinomain situ, and tumor volume was significantly reduced compared to the BBN (0.9 ± 0.1 mm3versus 112.5 ± 6.4 mm3). Also, it showed a reduced MDA/TAS ratio and BBN-induced serum CRP, TGF-β1, and CD31 were prevented. In conclusion, omega-3 fatty acids inhibit the development of premalignant and malignant lesions in a rat model of bladder cancer, which might be due to anti-inflammatory, antioxidant, anti-proliferative, and anti-angiogenic properties.
43
Rakhmanov, Rofail Salykhovich, Elena Sergeevna Bogomolova, and Denis Alekseevich Narutdinov. "Bioclimatic characteristics of the regions of the Russian region from the standpoint of assessing the health risk of the population by effective temperature." Sanitarnyj vrač (Sanitary Doctor), no. 4 (April 1, 2021): 38–46. http://dx.doi.org/10.33920/med-08-2104-04.
Abstract:
We calculated the effective temperatures based on 10-year data for temperatures (monthly average and minimum), wind speeds (monthly average and maximum) and relative air humidity in the climatic zones of the Krasnoyarsk Territory (subarctic No. 1) and temperate continental (Krasnoyarsk (object No. 2) and Minusinsk (3) We assessed the health risk.In winter, in the subarctic zone, the temperature is –23.3 ± 1.5 0 C (minimum –30.2 ± 2.1 0 C), in object No. 2 — –17.3 ± 1.6 0 C (–19.3 ± 1.0 0 С) and object No. 3 — –19.9 ± 1.4 0 С (–25.5 ± 1.9 0 С). In spring at object No. 1 it varied from –16.5 ± 1.7 0 С to + 1.6 ± 1, 0 0 С, object No. 2 — from –3.9 ± 0.9 0 С to + 9.4 ± 0.5 0 С, object No. 3 — from –4.5 ± 0.9 to + 10.6 ± 0.4. Temperatures ranged from + 8.2 ± 0.9 0 C to –17.8 ± 1.2 0 C (object No. 1), from + 9.4 ± 0.5 0 C to –7.5 ± 0.9 0 C and from +10.4 ± 0.4 0 C to –6.4 ± 1.0 0 C. In summer, the temperature was 19.9 ± 0.9 0 C, 18.8 ± 0.3 0 C, and 19.8 ± 0.4 0 C, respectively. Wind speed at object No. 3.6 ± 0.05 m/s in July increased to 5.4 ± 0.2 m/s in December (maximum 16.2 m/s); No. 2 in July 1.4 ± 0.05 m/s, in October-May 1.8 ± 0.2–2.1 ± 0.07 (maximum in December 10.1 ± 0.1 m/s); No. 3 minimum wind in January and February (1.1 ± 0.1 m/s), maximum 10.7 ± 0.6 m/s in May. A moderately dry climate is recorded during 2, 4 and 5 months. In the conditions of Krasnoyarsk and Minusinsk in the spring, humidity drops to the limits of dry air. Average effective temperatures indicated a possible risk of frostbite in the subarctic zone after 20–30 minutes within 2 months; at minimum temperatures and maximum winds in March, frostbite in 20–30 minutes, in November, December and February in 10–25 minutes; in January — in 5 minutes. In the Krasnoyarsk region in January frostbite is possible within 20–30 minutes, in Minusinsk in February in 20–30 minutes, in January 10–15 minutes. Heat stress is undefined.
44
Mayer, Frizzi, Franziska Heider, Florian Haasters, and Christoph Mehren. "Radiological and Clinical Outcomes after Anterior Cervical Discectomy and Fusion (ACDF) with an Innovative 3D Printed Cellular Titanium Cage Filled with Vertebral Bone Marrow." BioMed Research International 2022 (April 26, 2022): 1–8. http://dx.doi.org/10.1155/2022/6339910.
Abstract:
Study Design. Prospective single-center study. Objectives. To assess the clinical and radiological outcomes after ACDF with 3D printed cellular titanium cages filled with bone marrow and to compare the clinical and radiological results with the current scientific literature. Methods. ACDF was performed monosegmentally under standardized conditions. X-rays were analyzed to determine the range of motion, fusion rates, and subsidence preoperatively and 3 and 12 months postoperatively. Clinical outcome measurements included neck disability index (NDI), visual analogue scale (VAS) for brachialgia and cervicalgia, and patient satisfaction. Results. 18 patients were included in the study. The mean RoM decreased from 7.7 ° ± 2.6 preoperatively to 1.7 ° ± 1.1 ° after 3 months and 1.8 ° ± 1.2 ° 12 months after surgery. The fusion rates were at 94.4% after 3 and 12 months. The mean subsidence was 0.9 mm ± 0.5 mm 3 months postoperatively and 1.1 mm ± 0.5 mm 12 months after surgery. The mean NDI improved significantly from preoperatively to 12 months postoperatively ( 34.6 ± 6.2 and 3.4 ± 4.1 , respectively). The VAS-neck also showed a large improvement from 5.8 ± 2.2 before and 1.3 ± 1.4 12 months after surgery, as did the VAS-arm ( 6.4 ± 1.5 and 0.9 ± 1.6 , respectively). Patient satisfaction was high throughout the follow-up period. Conclusion. ACDF with a 3D printed titanium cage resulted in fast fusion without pathological subsidence. In comparison to other cage materials such as PEEK, the 3D printed titanium cage was noninferior in regard to its fusion rate and clinical results.
45
Trần, Thị Nương, Ngọc Khái Phạm, and Minh Hiếu Lê. "<span>HIỆU QUẢ CỦA VIÊN NANG KENU TD TRONG HỖ TRỢ ĐIỀU TRỊ ĐÁI THÁO ĐƯỜNG TÝP 2</span>." Tạp chí Dinh dưỡng và Thực phẩm 19, no. 6 (November 14, 2023): 20–26. http://dx.doi.org/10.56283/1859-0381/630.
Abstract:
Mục tiêu: Đánh giá hiệu quả của viên nang KENU TD trong hỗ trợ điều trị đái tháo đường týp 2. Phương pháp: Thử nghiệm lâm sàng ngẫu nhiên có đối chứng, nhãn mở được thực hiện trên 472 người bệnh đái tháo đường týp 2 đang điều trị ngoại trú bằng thuốc đái tháo đường. Nhóm can thiệp dùng thêm viên nang KENU TD trong 3 tháng (n=237). Hiệu quả của viên nang KENU TD về mức giảm HbA1c và kiểm soát glucose máu được phân tính bằng mô hình tuyến tính tổng quát hóa có điều chỉnh theo các yếu tố tuổi, giới tính, nơi sống, hoạt động thể lực, hút thuốc, uống rượu, BMI, huyết áp tối đa, HbA1c, glucose máu lúc đói, tiêm insulin, có biến chứng, cholesterol toàn phần, LDL-Cholesterol, triglyceride ở thời điểm trước can thiệp và sự thay đổi BMI sau can thiệp Kết quả: Giá trị HbA1c trung bình giảm 0,59% ở nhóm can thiệp và giảm 0,18% ở nhóm đối chứng (p=0,001). Sử dụng sản phẩm có thể đạt hiệu quả kiểm soát glucose máu tốt hơn so với không dùng sản phẩm với aRR (95%CI)= 0,65 (0,49-0,85). Kết luận: Sau 3 tháng dùng viên nang KENU TD có thể có hiệu quả giảm HbA1c ở bệnh nhân đái tháo đường týp 2 và hỗ trợ làm tăng khả năng đạt mục tiêu kiểm soát glucose máu.
46
DYKSTRA, PEARL A. "Philip Kreager and Elisabeth Schröder-Butterfill (eds), Ageing without Children: European and Asian Perspectives, Berghahn, Oxford, 2004, 276 pp., hbk $60.00, ISBN 1 57181 614 3, pbk $25.00, ISBN 1 84545 041." Ageing and Society 27, no. 2 (February 15, 2007): 311–12. http://dx.doi.org/10.1017/s0144686x06245720.
47
Zhao, Bai-Wei, Fei-Yang Zhang, Yun Wang, Guo-Ming Chen, Man Nie, Zhou-Kai Zhao, Xiao-Jiang Chen, Kai-Ming Jiang, Run-Cong Nie, and Ying-Bo Chen. "LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials." Cancers 14, no. 20 (October 11, 2022): 4975. http://dx.doi.org/10.3390/cancers14204975.
Abstract:
Objective: To compare the inhibition of LAG3-PD1 versus the inhibition of CTLA-4-PD1 in patients with previously untreated advanced melanoma. Methods: The individual participant data (IPD) were extracted from the KM plots using a graphical reconstructive algorithm. Log-rank, Cox proportional hazard model, Bayesian hierarchical model with time-varying hazard ratio (HR) effect, and restricted mean survival time (RMST) were performed to estimate survival benefits. Results: The CheckMate-067 (n = 630) and RELATIVITY-047 (n = 714) trials were included for analysis. The graphical reconstructive algorithm showed that IPD had similar HRs and log-rank values as the original plots. The HR of nivolumab plus relatlimab (LAG3 inhibitor) versus nivolumab plus ipilimumab (CTLA4 inhibitor) was 1.19 (95% confidence interval [CI] 0.96 to1.48). The 24-months RMST of nivolumab plus relatlimab versus nivolumab was 2.35 (95% CI 0.77–3.94) months, compared with 1.87 (95% CI, 0.25–3.49) months for nivolumab plus ipilimumab versus nivolumab. The Bayesian hierarchical model showed that patients treated with nivolumab plus relatlimab had earlier PFS benefits than those with nivolumab plus ipilimumab. Grade 3 or 4 treatment-related adverse events occurred in 18.9% of patients using nivolumab plus relatlimab and 55.0% of patients using nivolumab plus ipilimumab. Conclusions: These findings suggest that the PFS of LAG3-PD1 and CTLA4-PD1 inhibition were similar and LAG3-PD1 inhibition exhibited earlier survival benefit and lesser TRAEs.
48
Pereira, Marta Inez Rodrigues, Paulo Sergio Chagas Gomes, and Yagesh Bhambhani. "Número máximo de repetições em exercícios isotônicos: influência da carga, velocidade e intervalo de recuperação entre séries." Revista Brasileira de Medicina do Esporte 13, no. 5 (October 2007): 287–91. http://dx.doi.org/10.1590/s1517-86922007000500002.
Abstract:
INTRODUÇÃO: Pouco se sabe sobre o efeito da velocidade de execução e do intervalo entre séries sobre o desempenho no exercício contra-resistência. OBJETIVO: Comparar o número máximo de repetições até a fadiga voluntária (REPS) na cadeira extensora com o joelho dominante para diferentes cargas, velocidades e intervalos entre séries. MÉTODOS: Nove voluntários (35,8 ± 10,8 anos; 74,2 ± 16,7kg; 171,0 ± 10,0cm) reportaram ao laboratório para determinação de 1RM e REPS em seis situações, determinadas aleatoriamente e separadas por no mínimo 48h: uma série com 60% 1RM a 80°•s¹ e 25°•s-1; uma série com 80% 1RM a 25°•s¹; três séries com 80% 1RM a 80°•s-1 e intervalos de 3 min, 1 min e naquele que permitisse a estabilização da oxigenação muscular (RMox), medida por espectroscopia no infravermelho próximo. RESULTADOS: O teste t dependente mostrou que REPS foi significativamente (p < 0,05) maior na carga leve que na pesada, nas velocidades lenta (leve = 8,8 ± 1,3; pesada = 5,9 ± 0,9) e rápida (leve = 16,3 ± 3,9; pesada = 9,4 ± 1,9), e significativamente maior na velocidade rápida que na lenta, para ambas as cargas. A ANOVA 3x3 não mostrou diferença entre os intervalos na série 1 (3 min = 9,4 ± 1,9; 1 min = 10,8 ± 3,2; RMox = 10,1 ± 3,0), porém, houve diferenças significativas nas séries 2 e 3 entre 3 min (série 2 = 7,0 ± 1,7; série 3 = 6,4 ± 1,3) e 1 min (série 2 = 5,6 ± 1,1; série 3 = 4,8 ± 1,2), mas não entre RMox (série 2 = 6,4 ± 1,7; série 3 = 6,1 ± 1,5) e os demais intervalos. Nos três intervalos, REPS na série 1 foi significativamente maior que nas demais. CONCLUSÕES: O desempenho no exercício contra-resistência é afetado pela carga, velocidade e intervalo entre séries e é independente da recuperação em oxigenação muscular. A prescrição do exercício e a avaliação do desempenho devem levar essas variáveis em consideração frente aos objetivos propostos.
49
Colin, E. M., A. G. Uitterlinden, J. B. J. Meurs, A. P. Bergink, M. Van De Klift, Y. Fang, P. P. Arp, A. Hofman, J. P. T. M. van Leeuwen, and H. A. P. Pols. "Interaction between Vitamin D Receptor Genotype and Estrogen Receptor α Genotype Influences Vertebral Fracture Risk." Journal of Clinical Endocrinology & Metabolism 88, no. 8 (August 1, 2003): 3777–84. http://dx.doi.org/10.1210/jc.2002-021861.
Abstract:
In view of the interactions of vitamin D and the estrogen endocrine system, we studied the combined influence of polymorphisms in the estrogen receptor (ER) α gene and the vitamin D receptor (VDR) gene on the susceptibility to osteoporotic vertebral fractures in 634 women aged 55 yr and older. Three VDR haplotypes (1, 2, and 3) of the BsmI, ApaI, and TaqI restriction fragment length polymorphisms and three ERα haplotypes (1, 2, and 3) of the PvuII and XbaI restriction fragment length polymorphisms were identified. We captured 131 nonvertebral and 85 vertebral fracture cases during a mean follow-up period of 7 yr. ERα haplotype 1 was dose-dependently associated with increased vertebral fracture risk (P < 0.001) corresponding to an odds ratio of 1.9 [95% confidence interval (CI), 0.9–4.1] per copy of the risk allele. VDR haplotype 1 was overrepresented in vertebral fracture cases. There was a significant interaction (P = 0.01) between ERα haplotype 1 and VDR haplotype 1 in determining vertebral fracture risk. The association of ERα haplotype 1 with vertebral fracture risk was only present in homozygous carriers of VDR haplotype 1. The risk of fracture was 2.5 (95% CI, 0.6–9.9) for heterozygous and 10.3 (95% CI, 2.7–40) for homozygous carriers of ERα haplotype 1. These associations were independent of bone mineral density. In conclusion, interaction between ERα and VDR gene polymorphisms leads to increased risk of osteoporotic vertebral fractures in women, largely independent of bone mineral density.
50
Dawood, Fatimah S., Shikha Garg, Rebecca V. Fink, Margaret L. Russell, Annette K. Regan, Mark A. Katz, Stephanie Booth, et al. "Epidemiology and Clinical Outcomes of Hospitalizations for Acute Respiratory or Febrile Illness and Laboratory-Confirmed Influenza Among Pregnant Women During Six Influenza Seasons, 2010–2016." Journal of Infectious Diseases 221, no. 10 (December 26, 2019): 1703–12. http://dx.doi.org/10.1093/infdis/jiz670.
Abstract:
Abstract Background Pregnant women are at increased risk of seasonal influenza hospitalizations, but data about the epidemiology of severe influenza among pregnant women remain largely limited to pandemics. Methods To describe the epidemiology of hospitalizations for acute respiratory infection or febrile illness (ARFI) and influenza-associated ARFI among pregnant women, administrative and electronic health record data were analyzed from retrospective cohorts of pregnant women hospitalized with ARFI who had testing for influenza viruses by reverse-transcription polymerase chain reaction (RT-PCR) in Australia, Canada, Israel, and the United States during 2010–2016. Results Of 18 048 ARFI-coded hospitalizations, 1064 (6%) included RT-PCR testing for influenza viruses, 614 (58%) of which were influenza positive. Of 614 influenza-positive ARFI hospitalizations, 35% were in women with low socioeconomic status, 20% with underlying conditions, and 67% in their third trimesters. The median length of influenza-positive hospitalizations was 2 days (interquartile range, 1–4), 18% (95% confidence interval [CI], 15%–21%) resulted in delivery, 10% (95% CI, 8%–12%) included a pneumonia diagnosis, 5% (95% CI, 3%–6%) required intensive care, 2% (95% CI, 1%–3%) included a sepsis diagnosis, and <1% (95% CI, 0%–1%) resulted in respiratory failure. Conclusions Our findings characterize seasonal influenza hospitalizations among pregnant women and can inform assessments of the public health and economic impact of seasonal influenza on pregnant women.